(Q50943644)

English

Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy.

scientific article published on 9 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23729200

Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. (English)

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23729200

1 reference

based on heuristic

inferred from title

pancreatic cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Christin Wittwer

1

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23729200

Stefan Boeck

2

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23729200

Volker Heinemann

3

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23729200

Michael Haas

4

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23729200

Petra Stieber

5

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23729200

Dorothea Nagel

6

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23729200

Stefan Holdenrieder

7

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23729200

language of work or name

0 references

publication date

9 August 2013

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23729200

International Journal of Cancer

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23729200

133

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23729200

11

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23729200

2619-2630

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23729200

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Nucleosomes in pancreatic cancer patients during radiochemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

High-mobility group box 1 and cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

2011: the immune hallmarks of cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Analysis and verification of the HMGB1 signaling pathway

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Molecular characteristics of immunogenic cancer cell death.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Nucleosomes in serum as a marker for cell death

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Regression modelling strategies for improved prognostic prediction

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

The extracellular release of HMGB1 during apoptotic cell death

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Circulating nucleosomes and biomarkers of immunogenic cell death as predictive and prognostic markers in cancer patients undergoing cytotoxic therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnetic resonance imaging and angiography

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Functional characterisation of serum DNase I in MRL-lprlpr mice

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28294

21 January 2018

Identifiers

10.1002/IJC.28294

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23729200

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/23729200

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50943644&oldid=1719492380"